Filtered By:
Therapy: Statin Therapy

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 12097 results found since Jan 2013.

Inclisiran: A Review in Hypercholesterolemia
AbstractInclisiran (Leqvio®) is a first-in-class, subcutaneously administered, small interfering RNA (siRNA) that prevents hepatic synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9), thereby decreasing circulating low-density lipoprotein cholesterol (LDL-C). In the EU, inclisiran is indicated in adults with primary hypercholesterolemia or mixed dyslipidemia, as an adjunct to diet. It is intended for use in patients unable to reach LDL-C goals on maximally tolerated statin therapy, with or without other lipid-lowering therapies (LLTs). In patients who are statin intolerant or for whom a statin is contraindi...
Source: American Journal of Cardiovascular Drugs - March 4, 2023 Category: Cardiology Source Type: research

High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany
ConclusionIn this real-world patient population referred to German lipid clinics for elevated LDL-C levels, inclisiran demonstrated a high interindividual variability in LDL-C reductions. Further research is warranted to elucidate reasons for the interindividual variability in drug efficacy.Graphical abstract
Source: Clinical Research in Cardiology - July 9, 2023 Category: Cardiology Source Type: research

Repurposing Simvastatin in Parkinson's Disease Model: Protection Is throughout Modulation of the Neuro-Inflammatory Response in the < em > Substantia nigra < /em >
Int J Mol Sci. 2023 Jun 21;24(13):10414. doi: 10.3390/ijms241310414.ABSTRACTParkinson's disease is a neurodegenerative disorder characterized by oxidative stress and immune activation in the nigro-striatal pathway. Simvastatin regulates cholesterol metabolism and protects from atherosclerosis disease. Simvastatin-tween 80 was administered 7 days before sterotaxic intrastriatal administration of MPP+ (1-methyl-4-phenylpyridine) in rats. Fluorescent lipidic product formation, dopamine levels, and circling behavior were considered damage markers. Twenty-four hours and six days after, the animal group lesioned with MPP+ showed...
Source: Atherosclerosis - July 14, 2023 Category: Cardiology Authors: Mois és Rubio-Osornio Carmen T Gom éz-De León Sergio Montes Carmen Rubio Camilo R íos Antonio Monroy Jorge Morales-Montor Source Type: research

Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease: A Review of Current and Emerging Therapies
AbstractLipoprotein(a), or Lp(a), is structurally like low-density lipoprotein (LDL) but differs in that it contains glycoprotein apolipoprotein(a) [apo(a)]. Due to its prothrombotic and proinflammatory properties, Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis. Lp(a) levels are genetically determined, and it is estimated that 20-25% of the global population has an Lp(a) level ≥50 mg/dL (or ≥125 nmol/L). Diet and lifestyle interventions have little to no effect on Lp(a) levels. Lipoprotein apheresis is the only approved treatment for elevated Lp(a) but i...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 19, 2023 Category: Drugs & Pharmacology Authors: Ibrahim S. Alhomoud, Azita Talasaz, Anurag Mehta, Michael Kelly, Evan M. Sisson, John D. Bucheit, Roy Brown, Dave L. Dixon Tags: REVIEW Source Type: research

Statins for women with polycystic ovary syndrome not actively trying to conceive
CONCLUSIONS: The evidence for all main outcomes of this review was of very low certainty. Due to the limited evidence, we are uncertain if statins compared with placebo, or statins plus metformin compared with metformin alone, improve resumption of menstrual regularity. The trial evaluating statin plus OCP versus OCP alone reported neither of our primary outcomes. No other studies reported resumption of spontaneous ovulation. We are uncertain if statins improve hirsutism, acne severity, or testosterone. All trials that measured adverse events reported no significant differences between the groups.PMID:37462232 | PMC:PMC103...
Source: Cochrane Database of Systematic Reviews - July 18, 2023 Category: General Medicine Authors: Ting Xiong Eloise Fraison Eleni Kolibianaki Michael F Costello Christos Venetis Elena B Kostova Source Type: research

Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease: A Review of Current and Emerging Therapies
AbstractLipoprotein(a), or Lp(a), is structurally like low-density lipoprotein (LDL) but differs in that it contains glycoprotein apolipoprotein(a) [apo(a)]. Due to its prothrombotic and proinflammatory properties, Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis. Lp(a) levels are genetically determined, and it is estimated that 20-25% of the global population has an Lp(a) level ≥50 mg/dL (or ≥125 nmol/L). Diet and lifestyle interventions have little to no effect on Lp(a) levels. Lipoprotein apheresis is the only approved treatment for elevated Lp(a) but i...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 19, 2023 Category: Drugs & Pharmacology Authors: Ibrahim S. Alhomoud, Azita Talasaz, Anurag Mehta, Michael Kelly, Evan M. Sisson, John D. Bucheit, Roy Brown, Dave L. Dixon Tags: REVIEW Source Type: research

Predictive Modeling of HMG-CoA Reductase Inhibitory Activity and Design of New HMG-CoA Reductase Inhibitors
In this study, we developed two models for predicting HMGR inhibitory activity and OATP1B1 affinity to propose the chemical structure of a new therapeutic agent for hypercholesterolemia with both high inhibitory activity and high liver selectivity. HMGR inhibitory activity and OATP1B1 affinity prediction models were constructed with high prediction accuracy for the test data: r2 = 0.772 and 0.768, respectively. New chemical structures were then input into these models to search for candidate compounds. We found compounds with higher HMGR inhibitory activity and OATP1B1 affinity than rosuvastatin, the most recently develope...
Source: Atherosclerosis - August 7, 2023 Category: Cardiology Authors: Shigeyoshi Samizo Hiromasa Kaneko Source Type: research

Pharmacological interventions for asymptomatic carotid stenosis
CONCLUSIONS: Although there is no high-certainty evidence to support pharmacological intervention, this does not mean that pharmacological treatments are ineffective in preventing ischaemic cerebral events, morbidity, and mortality. High-quality RCTs are needed to better inform the best medical treatment that may reduce the burden of carotid stenosis. In the interim, clinicians will have to use other sources of information.PMID:37565307 | PMC:PMC10401652 | DOI:10.1002/14651858.CD013573.pub2
Source: Cochrane Database of Systematic Reviews - August 11, 2023 Category: General Medicine Authors: Caroline Nb Clezar Carolina Dq Flumignan Nicolle Cassola Luis Cu Nakano Virginia Fm Trevisani Ronald Lg Flumignan Source Type: research

Pravastatin for lowering lipids
CONCLUSIONS: Pravastatin lowers blood total cholesterol, LDL cholesterol and triglyceride in a dose-dependent linear fashion. This review did not provide a good estimate of the incidence of harms associated with pravastatin because of the lack of reporting of adverse effects in 48.4% of the randomized placebo-controlled trials.PMID:37721222 | PMC:PMC10506175 | DOI:10.1002/14651858.CD013673.pub2
Source: Cochrane Database of Systematic Reviews - September 18, 2023 Category: General Medicine Authors: Stephen P Adams Nima Alaeiilkhchi Sara Tasnim James M Wright Source Type: research

Statins for the primary prevention of cardiovascular disease.
CONCLUSIONS: Reductions in all-cause mortality, major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins. PMID: 23440795 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - March 2, 2013 Category: Journals (General) Authors: Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S Tags: Cochrane Database Syst Rev Source Type: research

Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis
Conclusions Our meta-analysis suggests a potentially beneficial effect of statins on prostate cancer patients treated with RT but not among radical prostatectomy patients. Although limited by the lack of randomized data, these results suggest that primary treatment modality should be considered in future studies examining associations between statins and oncologic outcomes.
Source: Annals of Oncology - May 21, 2013 Category: Cancer & Oncology Authors: Park, H. S., Schoenfeld, J. D., Mailhot, R. B., Shive, M., Hartman, R. I., Ogembo, R., Mucci, L. A. Tags: reviews Source Type: research